🇺🇸 FDA
Pipeline program

A-101 Topical Solution

A-101-WART-202

Phase 2 small_molecule completed

Quick answer

A-101 Topical Solution for Common Wart is a Phase 2 program (small_molecule) at Aclaris Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Aclaris Therapeutics
Indication
Common Wart
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials